130 related articles for article (PubMed ID: 9170817)
1. Serum 2',5'-oligoadenylate synthetase concentrations in acute and chronic hepatitis C.
Yang PM; Wang JT; Chiang BL; Lai MY; Chen DS
J Formos Med Assoc; 1997 May; 96(5):314-9. PubMed ID: 9170817
[TBL] [Abstract][Full Text] [Related]
2. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.
Giannelli G; Antonelli G; Fera G; Dianzani F; Schiraldi O
J Interferon Res; 1993 Feb; 13(1):57-60. PubMed ID: 8454912
[TBL] [Abstract][Full Text] [Related]
3. Changes of serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis C.
Solinas A; Cossu P; Poddighe P; Tocco A; Deplano A; Garrucciu G; Diana MS
Liver; 1993 Oct; 13(5):253-8. PubMed ID: 8259037
[TBL] [Abstract][Full Text] [Related]
4. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis.
Andreone P; Cursaro C; Gramenzi A; Buzzi A; Miniero R; Sprovieri G; Gasbarrini G
J Hepatol; 1994 Dec; 21(6):984-8. PubMed ID: 7699263
[TBL] [Abstract][Full Text] [Related]
5. [Changes of serum 2',5'-oligoadenylate synthetase activity and neopterin during interferon treatment for chronic hepatitis C].
Daito K; Suou T; Kawasaki H
Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):981-5. PubMed ID: 7563914
[No Abstract] [Full Text] [Related]
6. Serum 2',5'-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B.
Shindo M; Okuno T; Matsumoto M; Takeda M; Takino T; Sokawa J; Iwata A; Sokawa Y
Hepatology; 1988; 8(2):366-70. PubMed ID: 2451634
[TBL] [Abstract][Full Text] [Related]
7. Detection of 2',5' oligoadenylate synthetase activity in acute viral hepatitis with special reference to histologic features in the acute stage.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Apr; 26(2):162-9. PubMed ID: 1710193
[TBL] [Abstract][Full Text] [Related]
8. Strong transient expression of the type I interferon-induced MxA protein in hepatitis A but not in acute hepatitis B and C.
Jakschies D; Zachoval R; Müller R; Manns M; Nolte KU; Hochkeppel HK; Horisberger MA; Deicher H; Von Wussow P
Hepatology; 1994 Apr; 19(4):857-65. PubMed ID: 8138257
[TBL] [Abstract][Full Text] [Related]
9. Activity of the interferon-induced 2',5'-oligoadenylate synthetase in patients with chronic hepatitis C.
Pawlotsky JM; Hovanessian A; Roudot-Thoraval F; Lebon P; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
J Interferon Cytokine Res; 1995 Oct; 15(10):857-62. PubMed ID: 8564707
[TBL] [Abstract][Full Text] [Related]
10. 2',5' Oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during interferon treatment of chronic non-A, non-B hepatitis.
Okuno T; Shindo M; Arai K; Matsumoto M; Takeda M; Kashima K; Sokawa Y
Gastroenterol Jpn; 1991 Oct; 26(5):603-10. PubMed ID: 1752391
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of 2',5'-oligoadenylate synthetase activity in peripheral blood mononuclear cells and serum during acute exacerbation of chronic hepatitis B.
Shindo M; Okuno T; Arai K; Matsumoto M; Takeda M; Takino T; Sokawa Y
Hepatology; 1989 May; 9(5):715-9. PubMed ID: 2468593
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of soluble interferon Alfa/Beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C.
Mizukoshi E; Kaneko S; Kaji K; Terasaki S; Matsushita E; Muraguchi M; Ohmoto Y; Kobayashi K
Hepatology; 1999 Nov; 30(5):1325-31. PubMed ID: 10534358
[TBL] [Abstract][Full Text] [Related]
13. Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.
Pawlotsky JM; Hovanessian AG; Roudot-Thoraval F; Robert N; Bouvier M; Babany G; Duval J; Dhumeaux D
Antimicrob Agents Chemother; 1996 Feb; 40(2):320-4. PubMed ID: 8834873
[TBL] [Abstract][Full Text] [Related]
14. Effect of obesity on pharmacokinetics and biologic effect of interferon-alpha in hepatitis C.
Lam NP; Pitrak D; Speralakis R; Lau AH; Wiley TE; Layden TJ
Dig Dis Sci; 1997 Jan; 42(1):178-85. PubMed ID: 9009135
[TBL] [Abstract][Full Text] [Related]
15. [Activity of 2, 5-oligoadenylate synthetase in non-A, non-B hepatitis].
Karino Y; Sugawara T; Saga A; Matsushima T; Miyazaki T
Nihon Rinsho; 1988 Dec; 46(12):2715-9. PubMed ID: 2468003
[No Abstract] [Full Text] [Related]
16. Serum and urinary neopterin levels in patients with chronic active hepatitis B treated with interferon.
Daito K; Suou T; Kawasaki H
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):303-16. PubMed ID: 8008980
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia.
Musolino C; Grosso P; Alonci A; Allegra A; Orlando A; Cincotta M; Buda G; Squadrito G
Am J Hematol; 1993 May; 43(1):1-4. PubMed ID: 8317456
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha.
Carreño V; Tapia L; Ryff JC; Quiroga JA; Castillo I
J Med Virol; 1992 Jul; 37(3):215-9. PubMed ID: 1331310
[TBL] [Abstract][Full Text] [Related]
19. Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma.
Bruchelt G; Fierlbeck G; Schiebel U; Bogenschütz O; Rassner G; Niethammer D
Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):521-8. PubMed ID: 1457613
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of recombinant human alpha-interferon for chronic non-A, non-B hepatitis.
Kakumu S; Arao M; Yoshioka K; Ichimiya H; Murase K; Aoi T; Kusakabe A
Am J Gastroenterol; 1989 Jan; 84(1):40-5. PubMed ID: 2521421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
